Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
02 Aug 2017
Inappropriate prescription of anaerobic antibiotics to intensive care unit (ICU) patients admitted with pneumonia frequently occurs, with the prescription associated with prolonged length of stay (LOS) in the ICU, a study has found.
Pearl Toh, 01 Aug 2017
Daily intake of B vitamins did not improve cognitive function in patients with small vessel disease, in addition to previous findings that it was not protective against major vascular events in patients who had a recent stroke or transient ischaemic attack, according to a substudy of the VITATOPS* trial.

Rituximab effective, safe for pure membranous lupus nephritis

13 Sep 2017

Rituximab may be an effective treatment option for pure membranous lupus nephritis (MLN) while having a good tolerance profile, a new multicentre retrospective study has shown.

In the study sample of 15 systemic lupus erythematosus (SLE) patients with pure lupus nephritis (mean age 37 years; 87 percent female; median SLE duration 1.5 years), rituximab treatment was started following unresolved proteinuria lasting 3 to 6 months.

Over a median follow-up period of 29 (6 to 112) months, two patients experienced rituximab failure after 12 months of treatment, and two were unresponsive within the first 6 months of treatment.

Remission after a year of treatment was reported in 87 percent (n=13) of the cohort. Of these, 60 percent of patients (n=9) experienced complete remission, while the rest experienced only partial remission, yielding a cumulative property of remission of 73 and 87 percent at months 6 and 12, respectively. The median time to complete remission was 10 months.

Median proteinuria showed substantial changes, improving from 4.9 g protein/g creatinine at baseline to 0.2 g/g at 12 months and to 0.1 g/g at 24 months. Three patients (20 percent) who achieved complete remission experienced proteinuria relapse, resulting in a cumulative risk of relapse of 10 percent at 12 months and of 41 percent at 36 months.

Patients with pure MLN who received rituximab as therapy were identified from 27 medical centres across France. Those who had SLE were eligible. Exclusion criteria included membranous nephropathy and receiving high doses of corticosteroids or immunosuppressive therapy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
02 Aug 2017
Inappropriate prescription of anaerobic antibiotics to intensive care unit (ICU) patients admitted with pneumonia frequently occurs, with the prescription associated with prolonged length of stay (LOS) in the ICU, a study has found.
Pearl Toh, 01 Aug 2017
Daily intake of B vitamins did not improve cognitive function in patients with small vessel disease, in addition to previous findings that it was not protective against major vascular events in patients who had a recent stroke or transient ischaemic attack, according to a substudy of the VITATOPS* trial.